Fundies.
English

Molecular Pharmacology (USA) Ltd.

EDGAR
Quarterly report (10-Q) · filed 2014-11-13

53 filing records in this dataset, filed from 2003-06-20 to 2014-11-13. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist
Cash and cash equivalents
102 thousand USD Source
Exact value

102107 USD

Long-term debt including current maturities
Not available
Shares outstanding
Not available

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2014-11-13.

Financial data available through: 2005-10-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 4 of 11 periods available· newest 2005-10-31
  • Net income: 4 of 11 periods available· newest 2005-10-31
  • Operating cash flow: 2 of 11 periods available· newest 2005-10-31
  • capital expenditure: No compatible figures in this window
  • Total assets: 1 of 11 periods available· newest 2005-10-31
  • liabilities: No compatible figures in this window
  • Current assets: 1 of 11 periods available· newest 2003-10-31
  • Current liabilities: 3 of 11 periods available· newest 2005-10-31
  • Cash and cash equivalents: 4 of 11 periods available· newest 2005-10-31
  • long term debt: No compatible figures in this window
  • shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    +USD 13,680

    Prior period

    −USD 29,217

    –

    Current period

    −USD 15,537

    –

    Exact inputs and evidence

    -15537 − -29217 = 13680 USD

    -29217 USD · 2003-11-01 – 2004-10-31

    Inspect prior input Prior source

    -15537 USD · 2004-11-01 – 2005-10-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +USD 1,882

    Prior period

    −USD 12,969

    –

    Current period

    −USD 11,087

    –

    Exact inputs and evidence

    -11087 − -12969 = 1882 USD

    -12969 USD · 2003-11-01 – 2004-10-31

    Inspect prior input Prior source

    -11087 USD · 2004-11-01 – 2005-10-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2002 2001-11-01 – 2002-10-31
−USD 21,152
Exact value

Exact value: -21152 USD

2001-11-01 – 2002-10-31: -21152 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period.

2003 2002-11-01 – 2003-10-31
−USD 48,392
Exact value

Exact value: -48392 USD

2002-11-01 – 2003-10-31: -48392 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period.

2004 2003-11-01 – 2004-10-31
−USD 29,217
Exact value

Exact value: -29217 USD

2003-11-01 – 2004-10-31: -29217 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 12,969
Exact value

Exact value: -12969 USD

2003-11-01 – 2004-10-31: -12969 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2005 2004-11-01 – 2005-10-31
−USD 15,537
Exact value

Exact value: -15537 USD

2004-11-01 – 2005-10-31: -15537 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 11,087
Exact value

Exact value: -11087 USD

2004-11-01 – 2005-10-31: -11087 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

53 filings · 0 latest values · 0 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001191357, 1191357, edgar:1191357

Also known as BLUE HAWK VENTURES INC, Molecular Pharmacology (USA) LTD